Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
In 2016, the pharmaceutical industry based in Spain invested approximately 194 million euros ($219 million) in contracts with organizations and health professionals to further research and development (R&D) projects. 3 July 2017
Japanese drug majors Mitsubishi Tanabe Pharma and Daiichi Sankyo have been cleared to start selling Canalia, a combination therapy for type 2 diabetes, in Japan. 3 July 2017
The heart failure space across the seven key markets of the USA, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%. 3 July 2017
Teijin Pharma and French firm Ipsen have received approval from Japan’s medicines regulator to market Somatuline for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP NET). 3 July 2017
In a second deal with a pharma major in as many months, Exscientia, an innovative company at the forefront of artificial intelligence (AI)-driven drug discovery, has entered into a strategic drug discovery collaboration with GlaxoSmithKline. 3 July 2017
Takeda Pharmaceutical has selected three global CSR (corporate social responsibility) programs that emphasize prevention for health in developing and emerging countries. 3 July 2017
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) has welcomed the vote on the National Health Service (NHS) bill by the House of Representatives Plenum. 3 July 2017
Connecticut, USA-based biotech firm Cara Therapeutics has suffered a massive drop in share price after announcing disappointing top-line results from a Phase IIb study of its lead candidate CR845. 30 June 2017
The US Food and Drug Administration has accepted for review the resubmission of the New Drug Application for SUN-101/eFlow (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. 30 June 2017
The US Food and Drug Administration has approved Triptodur (triptorelin) for the treatment of pediatric patients two years and older with central precocious puberty (CPP). 30 June 2017
The US non-profit organization the Institute for Clinical and Economic Review (ICER) has released a new report which finds little evidence to demonstrate that abuse-deterrent opioids have an impact on opioid abuse. 30 June 2017
The Australian government continues to make medicines available and more affordable for Australians with new listings worth A$142 million ($108 million) being added to the Pharmaceutical Benefits Scheme (PBS) from July 1, 2017. 30 June 2017
Daiichi Sankyo has announced top-line results from NEUCOURSE, a Phase III clinical trial in patients with post-herpetic neuralgia, and the ALDAY Phase III clinical trials in patients with fibromyalgia. 30 June 2017
Against a backdrop of ever-increasing requests for Orphan Drug designation in the USA, the Food and Drug Administration today unveiled a strategic plan to eliminate the agency’s existing backlog of requests and ensure continued timely response to all new requests for designation with firm deadlines. 29 June 2017
The interim president and chief executive of Teva Pharmaceutical, Yitzhak Peterburg, has said that he believes the healthcare industry is undergoing “huge disruption.” 29 June 2017
The European Commission today launched its new European Union action plan to tackle antimicrobial resistance (AMR) – a growing threat that is responsible for 25,000 deaths in the EU every year. 29 June 2017
UK-based Heptares Therapeutics, a wholly-owned subsidiary of Japan’s Sosei Group, and PeptiDream have entered into a strategic collaboration to discover, develop and commercialize novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with an important role in inflammatory diseases. 29 June 2017
Netherlands-headquartered independent drugmaker Norgine says the US Food and Drug Administration has accepted and will review the company’s regulatory submission for Plenvu. 29 June 2017
The US Federal Trade Commission is currently accepting public comments on an application by Grifols, a Spain-based manufacturer of plasma-derived drugs, to amend the terms of a manufacturing agreement that was part of a 2011 FTC-ordered divestiture. 29 June 2017